Valneva SE (VALN) - Earnings growth in current year

Official company branding of Valneva SE (VALN)

The YoY earnings per share dynamics demonstrate cash flow volatility, where the value of 35.10 determines the parameter status. The financial stability of Valneva SE (VALN) depends on government contracts and regulatory timelines. Risks are linked to the trials of the Lyme disease vaccine and production disruptions. Growth prospects are based on expanding demand in the tourism sector and the treatment of rare infections.

VALN Valneva Corp Net earnings per share growth this year (07/04/2022 - 11/12/2026)

Analytical breakdowns and data insights for company Valneva SE (VALN)

- stock price and consensus target price:
Price Performance Chart Valneva Corp|VALN - Consensus Target
- market capitalization indicators:
Market Capitalization Valneva Vaccines|VALN - Total Company Value
- book capitalization data:
Net Assets per Share Valneva|VALN - Company Net Assets|Market Value to Book Value Ratio valneva.com|VALN - Company Total Assets
- debt and liquidity details:
Total Debt to Capital Valneva SE|VALN - Long-Term Debt to Equity|Short-Term Debt to Equity valneva.com|VALN - Company Debts|Debt to Book Value Ratio Valneva Vaccines|VALN - Company Long-Term Debts|Short-Term Debt Valneva|Quick Liquidity valneva.com
- earnings and multiples data:
VALN - Net Profit|Projected Future Earnings Valneva SE|VALN - Price to Earnings Ratio|Future Price to Earnings Multiple Valneva Vaccines|VALN - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Valneva Vaccines|VALN - Operating profit EBITDA|Net earnings per one share for the last twelve months Valneva|VALN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months valneva.com|VALN - Earnings growth in current year|Earnings growth forecast for next year Valneva SE
Basic company analysis:Valneva Corp
Manufactured product of valneva.com

This indicator measures the annual growth of net earnings per share, allowing investors to assess capital generation efficiency and business scaling rates. When analyzing the distribution of annual changes in earnings per share, one should look for sustainable growth, which for Valneva SE (VALN) is supported by long-term government defense contracts and stable demand for specialized vaccines within patent cycles.

Direct competitors

Gilead - Earnings per share increase in current year|Net earnings per share growth this year CDTX|Earnings growth in current year Novavax Pharma|Earnings per share growth in current year CureVac N.V. (CVAC)|Expected net earnings per share growth this year vir.bio|SIGA Technologies - Net earnings per share growth this year|Emergent BioSolutions Inc - Earnings per share growth in current year|Atea Pharmaceuticals Inc - Earnings growth in current year|IVVD - Earnings growth in current year|Enanta Pharmaceuticals (ENTA) - Earnings per share growth in current year|INO (inovio.com) - Earnings per share growth in current year|Earnings per share growth in current year HilleVax|Earnings per share growth this year KLRS (Kalaris Therapeutics Inc.)|Earnings growth in current year DYAI|NNVC - Earnings per share growth rate in current year|Talphera, Inc. - Net earnings per share growth this year|cocrystalpharma.com - Earnings per share growth in current year|Traws Therapeutics - Earnings growth in current year|DWTX - Earnings growth in current year|QLGN (Qualigen) - Net earnings per share growth this year|AlloVir - Earnings per share increase in current year|Earnings per share growth in current year VBI Vaccines, Inc.|Virios (VIRI) - Expected net earnings per share growth this year|Earnings growth in current year VXRT